| Literature DB >> 32941614 |
Usheer Kanjee1, Christof Grüring1, Prasad Babar2,3, Anosha Meyers1, Rashmi Dash2,3, Ligia Pereira2,3, Anjali Mascarenhas2,3, Mudit Chaand1, Gabriel W Rangel1, Martha A Clark1, Laura Chery2, Edwin Gomes3, Pradipsinh K Rathod2, Manoj T Duraisingh1.
Abstract
Plasmodium vivax has 2 invasion ligand/host receptor pathways (P. vivax Duffy-binding protein/Duffy antigen receptor for chemokines [DARC] and P. vivax reticulocyte binding protein 2b/transferrin receptor [TfR1]) that are promising targets for therapeutic intervention. We optimized invasion assays with isogenic cultured reticulocytes. Using a receptor blockade approach with multiple P. vivax isolates, we found that all strains utilized both DARC and TfR1, but with significant variation in receptor usage. This suggests that P. vivax, like Plasmodium falciparum, uses alternative invasion pathways, with implications for pathogenesis and vaccine development.Entities:
Keywords: zzm321990 Plasmodium vivaxzzm321990 ; DARC; TfR1; parasite invasion; receptor blockade
Mesh:
Substances:
Year: 2021 PMID: 32941614 PMCID: PMC8161644 DOI: 10.1093/infdis/jiaa592
Source DB: PubMed Journal: J Infect Dis ISSN: 0022-1899 Impact factor: 5.226